Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jul 20;28(21):3442-7.
doi: 10.1200/JCO.2009.27.8267. Epub 2010 May 24.

Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls

Michael A Andrykowski  1 , Jessica L Burris, Erin Walsh, Brent J Small, Paul B Jacobsen
Affiliations
Randomized Controlled Trial

Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls

Michael A Andrykowski et al. J Clin Oncol. .

Abstract

Purpose: The trend toward personalized medicine will involve cancer treatment increasingly being tailored to the genetic characteristics of individuals. However, the availability of genetic information does not imply this information is desired or would impact treatment decision making.

Methods: One hundred sixty breast cancer survivors (BC group) and 205 healthy controls (HC group) were randomly assigned to respond to two different clinical scenarios varying in genetic-related risk of cognitive impairment (CI; little v very likely) and severity of CI (little v moderate problem) after chemotherapy. Ratings of the importance of being told this genetic information (information importance) and the likelihood this information would affect their decision to receive chemotherapy (information impact) were obtained.

Results: Results indicated the importance ascribed to genetic information was greatest when CI likelihood and severity were both high or low (P < .05). Information impact ratings were not sensitive to differences in CI likelihood or severity; the BC group was less likely to indicate genetic information would affect their decision to receive chemotherapy than the HC group (P < .001).

Conclusion: Results suggest lessened enthusiasm for genetic information that maintains or increases uncertainty about a specific course of action and highlight the importance of including clinically relevant groups in treatment decision-making research that employs hypothetical scenarios. Although women generally believe it is important to receive genetic information, they might benefit from assistance (eg, decision aid) in the difficult task of integrating information about survival and risk for adverse late effects from cancer treatment.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Flow chart showing study participation. HC, healthy control group; BC, breast cancer group.
Fig 2.
Fig 2.
Cognitive impairment (CI) risk by CI severity interaction for information importance ratings.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Guttmacher AE, Collins FS. Genomic medicine: A primer. N Engl J Med. 2002;347:1512–1520. - PubMed
    1. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med. 2003;348:50–58. - PubMed
    1. Blackwood MA, Weber BL. BRCA1 and BRCA2: From molecular genetics to clinical medicine. J Clin Oncol. 1998;16:1969–1977. - PubMed
    1. Fasouliotis SJ, Schenker JG. BRCA1 and BRCA2 gene mutations: Decision making dilemmas concerning testing and management. Obstet Gynecol Surv. 2000;55:373–384. - PubMed
    1. Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: What we know and what we need. Nat Med. 2001;7:552–556. - PubMed

Publication types